The Manufacturers Life Insurance Company Invests $57,000 in scPharmaceuticals Inc. (NASDAQ:SCPH)

The Manufacturers Life Insurance Company bought a new position in scPharmaceuticals Inc. (NASDAQ:SCPHFree Report) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 12,411 shares of the company’s stock, valued at approximately $57,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Balanced Rock Investment Advisors LLC increased its position in scPharmaceuticals by 10.3% in the second quarter. Balanced Rock Investment Advisors LLC now owns 63,130 shares of the company’s stock worth $275,000 after buying an additional 5,882 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in scPharmaceuticals by 266.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company’s stock worth $316,000 after acquiring an additional 52,870 shares in the last quarter. Bank of New York Mellon Corp raised its stake in scPharmaceuticals by 15.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company’s stock worth $375,000 after acquiring an additional 11,269 shares during the period. Bank of Montreal Can purchased a new position in scPharmaceuticals during the second quarter valued at approximately $1,544,000. Finally, Rice Hall James & Associates LLC lifted its holdings in scPharmaceuticals by 76.9% during the second quarter. Rice Hall James & Associates LLC now owns 497,227 shares of the company’s stock valued at $2,163,000 after purchasing an additional 216,122 shares in the last quarter. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

scPharmaceuticals Stock Up 1.6 %

NASDAQ SCPH opened at $3.25 on Wednesday. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. scPharmaceuticals Inc. has a 12 month low of $3.08 and a 12 month high of $6.71. The stock’s 50 day moving average is $3.88 and its 200 day moving average is $4.36. The stock has a market cap of $162.63 million, a PE ratio of -1.71 and a beta of 0.14.

Analyst Upgrades and Downgrades

SCPH has been the topic of several recent analyst reports. Craig Hallum decreased their price objective on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a report on Thursday, November 14th.

Get Our Latest Analysis on scPharmaceuticals

scPharmaceuticals Profile

(Free Report)

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.

Further Reading

Want to see what other hedge funds are holding SCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for scPharmaceuticals Inc. (NASDAQ:SCPHFree Report).

Institutional Ownership by Quarter for scPharmaceuticals (NASDAQ:SCPH)

Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.